Summary
The news is advocating an interesting finding from the third phase of a clinical trial to confirm the efficacy and safety profile of Linagliptin to treat patients with type 2 diabetes. The finding supporting the effective use of Linagliptin to treat diabetes type 2 from the phase III pivotal trials has been gathered from a large population groups across the world, thereby raising the culture-free clinical property profile of this drug.
Analysis
The news is showing a thoughtful summary of the intervention taken by Boehringer Ingelheim for advancing the efficacy and clinical profile of Linagliptin to treat patients with type 2 diabetes. The phase III clinical trial following on the phase II clinical trial was indeed reconfirming the effectiveness of Linagliptin to treat diabetes type 2 patients in conjunction with other commonly used diabetes treatments including metformin, sulfonylureas and thiazolinediones (TZDs). The news however, did not provide the 'effect size' of Linagliptin, independent of the effects from other drugs, as such, the question is, how effective Linagliptin is to treat diabetes type 2 in the absence of any other treatment drugs in a treatment/care plan?
The news is very promising for treating diabetes patients across the world due to the wide application to a large population groups, thereby canceling out the narrow focus and applicability issues in the clinical trial design.
Diabetes is still the most common disease irrespective of geographical locations, hence any therapeutic movement to treat this disease will be a pragmatic step to offer relieve from this ever increasing disease at an early stage, minimizing the side effects and effects caused by long-term use of any drug for treatment.
The data from the clinical trial III is still ongoing, therefore, a full analysis of the effectiveness of Linagliptin to treat diabetes type 2 disease is not possible. Nevertheless, the information provided so far to confirm the clinical efficacy of this drug is indicative of the potential benefits from the use of this drug for all population groups.
This author consults with leading institutions through GLG
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
